Understanding why mood symptoms flare in the luteal phase — the second half of your menstrual cycle — is key to understanding PMDD. This review pulls together evidence showing that progesterone itself isn't necessarily the villain. Instead, the problem may lie in how your brain processes one of progesterone's breakdown products: a molecule called allopregnanolone. Allopregnanolone normally has calming, anti-anxiety, and antidepressant effects by acting on the brain's main "slow-down" system (GABA receptors). When levels are too low, unstable, or when the brain's receptors don't respond properly, mood symptoms can emerge.
One of the most striking findings discussed is that the relationship between allopregnanolone and mood follows a U-shaped curve. Very low and very high levels seem to be okay, but the middling, fluctuating levels typical of the luteal phase appear to trigger negative mood in susceptible people. This helps explain why PMDD symptoms track so closely with the days right before your period, when progesterone — and therefore allopregnanolone — is rising and then dropping.
The review also highlights promising new treatments. Brexanolone, a synthetic form of allopregnanolone, was FDA-approved for postpartum depression after showing rapid and significant improvement in clinical trials. Sepranolone, a newer drug that blocks allopregnanolone's problematic effects at GABA receptors, reduced PMDD symptoms in early trials with an effect size similar to SSRIs. Interestingly, SSRIs themselves may partly work in PMDD by boosting the brain's own allopregnanolone.
Another important takeaway is the distinction between natural (bioidentical) progesterone and synthetic progestins found in many hormonal contraceptives. Synthetic progestins cannot be converted into allopregnanolone, which may explain why some hormonal birth control worsens mood for people with PMDD. If you've noticed mood changes on hormonal contraception, this research helps explain why that might happen. As always, talk with your healthcare provider about what's right for you.
Key findings
- Allopregnanolone, a natural progesterone metabolite, directly interacts with GABA-A receptors at nanomolar concentrations and produces significant antidepressant, anti-stress, sedative, and anxiolytic effects
- Brexanolone (synthetic allopregnanolone) showed significant and clinically meaningful reductions in HAM-D total score at 60 hours compared with placebo in two phase III trials (N=375) for postpartum depression and received FDA approval
- Sepranolone (UC1010), a GABA-A receptor modulating steroid antagonist, reduced PMDD symptoms significantly better than placebo in a phase II trial (N=126 women with PMDD), with effect sizes comparable to SSRIs and drospirenone-containing oral contraceptives
- In a study of 122 healthy reproductive-age women, higher luteal progesterone levels were associated with decreased aggression, irritability, and fatigue, and peak luteal progesterone negatively correlated with these symptoms
- The severity of mood symptoms in women follows an inverted U-shaped curve relative to serum allopregnanolone concentrations — negative mood symptoms peak at endogenous luteal phase levels, while low and high concentrations have less mood impact
- Non-bioidentical progestins suppress ovulation and cannot be metabolized into neuroactive mood-improving derivatives like allopregnanolone, which may explain their paradoxical negative mood effects
Methods, briefly
Narrative review of literature published up to end of 2021. Searched Medline (via PubMed) using keywords including 'luteal phase deficiency,' 'premenstrual dysphoric disorder,' 'progesterone,' 'affective disorder,' 'allopregnanolone,' and 'postpartum depression.' Preference was given to meta-analyses, systematic reviews, and RCTs, supplemented by prospective studies, cohort studies, and clinical guidelines. No specific number of included studies stated; key studies summarized ranged from N=16 to N=2556.
Limitations to keep in mind
- Narrative review without systematic methodology or risk-of-bias assessment
- Many of the primary studies cited had small sample sizes and conflicting results regarding progesterone and allopregnanolone levels in mood disorders
- The evidence for the role of allopregnanolone in perinatal mood disorders is described as inconclusive by the authors themselves
- Research on progesterone dosing, route of administration, and timing relative to ovulation remains insufficient to draw definitive treatment conclusions
- The review acknowledges that prior meta-analyses on progesterone for PMS were based on limited and methodologically weak trials
The latest PMDD research, in your pocket
The app’s research feed is updated daily with newly published, peer-reviewed PMDD work - summarized in plain language.